Abstracts tagged "Infection"

Abstract Number: 2614 • ACR Convergence 2024
Risk of New Onset of Immune-Mediated Diseases After Sars-Cov-2 Infection: A Systematic Review and Meta-Analysis
Ana Milena Gil¹, Julián Barahona-Correa², Jorge Bruce Flórez-Suárez³, Daniel Fernández-Ávila⁴ and Zulma Cucunubá¹, ¹Department of Clinical Epidemiology and Biostatistics, Pontificia Universidad Javeriana, Bogotá, Colombia, ²Division of Rheumatology, Pontificia Universidad Javeriana - Hospital Universitario San Ignacio, Bogotá, Colombia, ³Department of Immunology, Universidad Nacional de Colombia, Bogotá, Colombia, ⁴5Hospital San Ignacio, Colombia, BOGOTA, Colombia
Background/Purpose: The association between SARS-CoV-2 infection and the new onset of immune-mediated diseases is a topic of interest given the conflicting evidence available. This systematic…
Abstract Number: 0249 • ACR Convergence 2024
Real World Evidence on the Safety of the Adjuvanted Recombinant Zoster Vaccine in Patients with Rheumatic Diseases – Preliminary Results from a Prospective Multicenter Observational Greek Study
Christos Koutsianas¹, Anastasia Apanomeritaki², Evgenia Mavrea¹, Niki-Violeta Dimopoulou¹, Maria Nitsa¹, CHRISTINA TSALAPAKI¹, Iro-Ioanna Giannakopoulou² and Dimitrios Vassilopoulos¹, ¹Clinical Immunology-Rheumatology Unit, 2nd Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, Hippokration General Hospital, Athens, Greece, ²Rheumatology Clinic, General Hospital Asklepieio Voulas, Voula, Attiki, Greece
Background/Purpose: Patients with rheumatic diseases (RD) are at increased risk for herpes zoster (HZ) due to disease -related aberrant immune response, comorbid conditions and anti-rheumatic…
Abstract Number: 0625 • ACR Convergence 2024
Trends, Outcomes, and Predictors of Mortality in Patients with SLE Hospitalized for Influenza
Asim Khanfar¹, Shiamak Cooper², Ali Mohamed³, Tanvi Borse⁴ and Sarah Nalwalla⁵, ¹Rochester General Hospital, Rochester, NY, ²Rochester General Hospital, Irondequoit, NY, ³Internal Medicine Resident, Rochester General Hospital, Rochester, NY, ⁴Parkview Health, Fort Wayne, IN, ⁵Seth GSMC and KEM Hospital, Mumbai, India
Background/Purpose: SLE is a chronic autoinflammatory condition affecting multiple organ systems. Patients with SLE are at a higher risk for infection compared to the general…
Abstract Number: 1598 • ACR Convergence 2024
Projecting the Impact of Standard, Reduced-Dose, and Minimal-Dose Glucocorticoid Regimens in the Treatment of ANCA-Associated Vasculitis Using Simulation Modeling
Naomi Patel¹, Aaron Wu¹, Shruthi Srivatsan¹, Eli Miloslavsky², Peter Merkel³, John Stone⁴, Hyon K. Choi⁵, Emily Hyle¹ and Zachary Wallace², ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Newton, MA, ³University of Pennsylvania, Philadelphia, PA, ⁴Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁵Massachusetts General Hospital, Lexington, MA
Background/Purpose: Glucocorticoids (GCs) remain a cornerstone of treatment of ANCA-associated vasculitis (AAV) but predispose people to infectious, metabolic, and other toxicities. We projected the long-term…
Abstract Number: 2616 • ACR Convergence 2024
Associations of Circulating Inflammatory Cytokines with Long COVID Among Patients with Systemic Autoimmune Rheumatic Diseases
Jeffrey Sparks¹, Xiaosong Wang², Pui Lee³, Kailey Brodeur⁴, Miao Lin⁵, Naomi Patel⁵, Yumeko Kawano⁶, Abigail Schiff⁷, Andrew King⁵, Jennifer Hanberg⁶, Shruthi Srivatsan⁵, Emily Kowalski⁶, Colebrook Johnson⁵, Kathleen Vanni⁶, Zachary Williams⁵, Grace Qian², Caleb Bolden⁵, Kevin Mueller⁶, Katarina Bade⁶, Alene Saavedra⁶, Rathnam Venkat⁸ and Zachary Wallace⁹, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, ²Brigham and Women’s Hospital, Boston, MA, ³Boston Children's Hospital, Newton, MA, ⁴Boston Children's Hospital, Cumberland, RI, ⁵Massachusetts General Hospital, Boston, MA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital, Cambridge, MA, ⁸Tufts University School of Medicine, Boston, MA, ⁹Massachusetts General Hospital, Newton, MA
Background/Purpose: While the incidence of severe acute COVID-19 has decreased, post-acute sequelae of COVID-19 characterized by prolonged symptoms, or ‘long COVID,’ is common and associated…
Abstract Number: 0251 • ACR Convergence 2024
T-SPOT.TB and TST in Diagnosing Active Tuberculosis in Patients with Rheumatic Immune Diseases: A Fully Paired Comparative Diagnostic Test Accuracy Study
Lifan Zhang, Yuanchun Li, Hangxing Wang and Xiaoqing Liu, Peking union medical college hospital, Beijing, China
Background/Purpose: Patients with Rheumatic Immune Diseases (RD) are at high risk for developing active tuberculosis (ATB). Accurate and timely diagnosis of ATB in RD patients…
Abstract Number: 0693 • ACR Convergence 2024
Behind the Bronchiectasis in Systemic Sclerosis. Prevalence and Risk Factors
Miriam Retuerto Guerrero¹, Clara Moriano², Paula Perez Garcia³, cristiana sieiro santos⁴ and elvira Diez álvarez³, ¹Complejo Asistencial Universitario de León, Leon, Spain, ²Hospital León, LEON, Spain, ³Complejo Asistencial Universitario de Leon, Leon, ⁴Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain
Background/Purpose: Bronchiectasis (BC) has been observed in association with Systemic Sclerosis (SSc). Esophageal dysmotility, immunosuppressive drugs and the direct effect of collagen deposition in the…
Abstract Number: 1705 • ACR Convergence 2024
Deep Phenotyping Characterization of Peripheral Natural Killer Cells Reveals Impaired Cytotoxicity and Exhaustion During VEXAS Syndrome
Paul Breillat¹, Carbone Francesco², Possémé Céline³, Marie Templé⁴, Aurélien Corneau⁵, Marine Luka², Camille Gobeaux⁶, Rodéreau Outh⁷, Estibaliz Lazaro⁸, Guillaume Le Guenno⁹, François Lifermann¹⁰, Marie Berleur¹¹, Melchior Le Mene⁴, Chloé Friedrich⁴, Cédric Lenormand¹², Thierry Weitten¹³, Vivien Guillotin¹⁴, Barbara Burroni⁶, Jeremy Boussier¹⁵, Lise Willems⁶, Léa Dionet¹⁶, Tharaux Pierre-Louis¹⁶, Darragh duffy¹⁷, Mickael Ménager¹⁸, Olivier Kosmider⁴ and Benjamin Terrier¹⁹, ¹Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), INSERM U970, Université de Paris, PARIS, France, ²Institut Imagine, Paris, France,, Paris, France, ³Institut Pasteur, Paris, France, Paris, France, ⁴Hematology Laboratory, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris Cité, Cochin Hospital, Paris, France, Paris, France, ⁵Sorbonne Université, Paris, France, ⁶Cochin Hospital, Paris, France, Paris, France, ⁷CH, Perpignan, France,, Perpignan, France, ⁸Bordeaux University Hospital, Pessac, France, ⁹CHU, Clermont-Ferrand, France,, Clermont-Ferrand, France, ¹⁰Dax Hospital, Dax, France, Dax, France, ¹¹CHU Bichat, Paris France, Paris, France, ¹²CHRU, Strasbourg, France, Strasbourg, France, ¹³CHIGAS, Gap, France, Gap, France, ¹⁴CHU Bordeaux, Bordeaux, France, Bordeaux, France, ¹⁵Sorbonne University, Paris, France, ¹⁶Paris Cardiovascular Research Center, INSERM U970, Paris, France, ¹⁷Translational Immunology Unit, Institut Pasteur, Université Paris-Cité, Paris, France, Paris, France, ¹⁸Institut Imagine, Paris, France, Paris, France, ¹⁹Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is a severe auto-inflammatory disorder associated with acquired mutations in the UBA1 gene that occur in hematopoietic stem cells…
Abstract Number: 2676 • ACR Convergence 2024
Timeframe for Initiating Methotrexate and Vaccine Response Against Pneumococcus in Rheumatoid Arthritis: The VACIMRA Study
Jacques MOREL¹, Emmanuelle Dernis², christian roux³, Christophe Richez⁴, OLIVIER BROCQ⁵, Bruno Fautrel⁶, Carine SALLIOT⁷, Olivier Vittecoq⁸, Xavier Mariette⁹, Frédéric LIOTE¹⁰, Slim Lassoued¹¹, Cécile Gaujoux-Viala¹², Arnaud Constantin¹³, MArtin Soubrier¹⁴, Valerie Devauchelle¹⁵, Vincent Goeb¹⁶, Jacques-Eric Gottenberg¹⁷, Hubert Marotte¹⁸, Annouc Rémy Moulard¹, Corinne Merle de Boever¹, Héléna Huguet¹, Odile Launay¹⁹, Florence Galtier¹ and Marie Christine Picot¹, and F-CRIN networks iREIVAC and CRI-IMMIDIATE, ¹CHU and University of Montpellier, Montpellier, France, ²CH LE MANS, LE MANS, Pays de la Loire, France, ³rheumatology department, university Cote d'Azur, nice, France, ⁴Université de Bordeaux, Bordeaux, France, ⁵Service de Rhumatologie, centre hospitalier Princesse-Grâce, Monaco, Monaco, ⁶INSERM, UMRS 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Sorbonne University – Assistance Publique-Hôpitaux de Paris, Département de Rhumatologie, Hôpital Pitié-Salpêtrière, Paris, Ile-de-France, France, ⁷CHU and University of Orléans, Orléans, France, ⁸CHU and University of Rouen, Rouen, France, ⁹Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, ¹⁰CHU and University of Paris Nord, Paris, France, ¹¹CH of Cahors, Cahors, France, ¹²CHU Nîmes, Nïmes, Languedoc-Roussillon, France, ¹³Hôpitaux de Toulouse, Toulouse, France, ¹⁴Gabriel-Montpied Hospital, Clermont-ferrand, France, ¹⁵UBO, Brest, France, ¹⁶CHu and University of Amiens, Ameins, France, ¹⁷Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ¹⁸Université Jean Monnet, CHU Saint-Etienne, Mines Saint-Etienne, INSERM SAINBIOSE 1059, Saint-Etienne, France, ¹⁹Centre d’Investigation Clinique en Vaccinologie (CIC Cochin Pasteur), Hôpital Cochin, Paris, Ile-de-France, France
Background/Purpose: Pneumococcal vaccination is recommended for patients with chronic inflammatory rheumatism treated with immunosuppressants. Methotrexate (MTX) is the first-line treatment used in rheumatoid arthritis (RA),…
Abstract Number: 0253 • ACR Convergence 2024
Outcomes of Respiratory Syncytial Virus Infection in Patients with Systemic Autoimmune Rheumatic Diseases
Justine Enns¹, Shruthi Srivatsan¹, Bohang Jiang¹, Miao Lin¹, Emily Kowalski², Naomi Patel¹, Xiaosong Wang³, Zachary Williams¹, Grace Qian³, Jennifer Hanberg¹, Colebrook Johnson¹, Madison Negron¹, Katarina Bade², Alene Saavedra², Kevin Mueller², Kathleen Vanni³, Jeffrey Sparks⁴ and Zachary Wallace⁵, ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women’s Hospital, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, ⁵Massachusetts General Hospital, Newton, MA
Background/Purpose: Respiratory Syncytial Virus (RSV) can cause a severe respiratory illness, especially in older adults and those with significant comorbidities. In June 2023 the US…
Abstract Number: 0806 • ACR Convergence 2024
Rotavirus Vaccine in Offspring Exposed to Tumour Necrosis Factor Inhibitors During the Third Trimester Does Not Increase Diarrhea-Associated Healthcare Events
Leah K. Flatman¹, Sasha Bernatsky², Isabelle Malhamé³, Yvan St-Pierre⁴, Olga Basso¹, Anick Bérard⁵ and Evelyne Vinet³, ¹McGill University, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University Health Center, Montreal, QC, Canada, ⁵Université de Montréal, Montreal, QC, Canada
Background/Purpose: Until recently, best practice guidelines recommended withholding rotavirus vaccine in offspring exposed in utero to any TNFi until 6 months of age due to fears of…
Abstract Number: 1716 • ACR Convergence 2024
Comparing the Risk of Severe Infections Associated with Different Classes of Biologic or Targeted Synthetic Agents for Inflammatory Arthritis: A Population-based Study
Kasra Moolooghy¹, Hui Xie², Yufei Zheng³, J. Antonio Avina-Zubieta¹ and Diane Lacaille¹, ¹Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Canada, Simon Fraser University, Vancouver, BC, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada
Background/Purpose: Various classes of biologic and targeted synthetic DMARDs (b/tsDMARDs) are now available for treatment of inflammatory arthritis (IA), but little information on their relative…
Abstract Number: 0254 • ACR Convergence 2024
Rheumatic Manifestations in Patients with Hansen’s Disease Treated with Multidrug Antibiotic Therapy
Pedro Gil De Rubio Cruz¹, Andrea Lastra-Annexy², Natalia Pelet Del Toro¹, Luis Vilá¹ and Aida Quintero-Noriega¹, ¹University of Puerto Rico Medical Sciences Campus, San Juan, PR, ²Universidad Central del Caribe School of Medicine, Bayamón, PR
Background/Purpose: Hansen’s Disease (HD), also known as leprosy, is a chronic granulomatous infection caused by Mycobacterium leprae. A wide range of rheumatic manifestations has been…
Abstract Number: 0829 • ACR Convergence 2024
Epstein-Barr Virus Infection Triggers Hyperinflammation and Cytokine Storm in Healthy Children
Kailey Brodeur¹, Meng Liu², Rachel Weng², Evan Hsu², Lauren Henderson³, Fatma Dedeoglu², Jane Newburger³, Peter Nigrovic⁴, Mary Beth Son⁴ and Pui Lee⁵, ¹Boston Children's Hospital, Cumberland, RI, ²Boston Children's Hospital, Boston, MA, ³Boston Children's Hospital, Watertown, MA, ⁴Boston Children's Hospital, Brookline, MA, ⁵Boston Children's Hospital, Newton, MA
Background/Purpose: Epstein-Barr virus (EBV) is common pathogen responsible for infectious mononucleosis but also triggers hemophagocytic lymphohistiocytosis (HLH). This variation in the immune response to EBV…
Abstract Number: 1729 • ACR Convergence 2024
Prophylaxis Against Pneumocystis Jerovecii Pneumonia for Patients with Systemic Autoimmune Diseases: Analysis of the Veterans Affairs Database
Karolina Lungova¹, Katherine Sherman², Mahum Mirza¹, Rohan Mehta¹ and Michael Putman³, ¹Medical College of Wisconsin, Milwaukee, WI, ²Research Division, Zablocki Veterans Affairs, Milwaukee, ³The Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Pneumocystis jirovecii Pneumonia (PJP) is an opportunistic infection that may affect immunocompromised patients. PJP prophylaxis has been recommended for some autoimmune diseases but not others.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].